Oculis
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Oculis sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Oculis: 8 sponsored US clinical trials, 2 recruiting.
Oculis sponsors 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 3 completed. 4 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetic Macular Edema, with 2 trials.
Upper-quartile sponsor footprint
Oculis sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
NCT07623668
A Clinical Study Evaluating Licaminlimab for Dry Eye Disease
NCT07548632
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)
NCT06172257
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
NCT05066997
Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery
NCT06128369
Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease
NCT05896670
A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
NCT05147233
OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
NCT04130802
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
| Phase 3 | 4 |
Therapeutic Areas
What is open in the Oculis pipeline
2 recruiting of 8 indexed (25% open); 3 completed (38%).
Phase mix: 4 late (III/IV) vs 4 early (I/II) (balanced across stages).
Top condition: Diabetic Macular Edema (2 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Oculis: open-pipeline peers nationwide
Peers matched on 8 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Oculis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 25% open enrollment (± trial volume)
- Abdul Latif Jameel Poverty Action Lab · 25% recruiting · 4 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
- Advocate Hospital System · 25% recruiting · 4 trials
Related
What to do with this Oculis page
8 registered trials is a research-attention snapshot, not an endorsement of Oculis or any single study.
- 2 of Oculis's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Diabetic Macular Edema is the condition Oculis studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetic Macular Edema trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Oculis pipeline card: 8 registered trials from official public datasets.Report a data error.